Carbonic anhydrase inhibitor 14 (Compound 8b) is a potent CA inhibitor, exhibiting K i values of 1203, 99.7, 9.4, and 27.7 nM against hCA I, hCA II, hCA IX, and hCAXII, respectively. Additionally, it effectively inhibits CDK2 with an IC 50 of 20.3 μM. Furthermore, Carbonic anhydrase inhibitor 14 demonstrates significant antitumor activity [1].
hCAXII-IN-1 demonstrates selective inhibition of tumor-related subtypes HCA IX and XII, making it potential leading molecules in the development of novel cancer therapeutic drugs with new mechanisms of action.
hCAXII-IN-5 (compound 6o) is a highly effective and specific inhibitor of hCAXII. The compound exhibits impressive binding affinities, with Ki values of >10000, >10000, 286.1, and 1.0 nM for hCAI, hCAII, hCAIX, and hCAXII, respectively [1].